Potentiating antilymphoma efficacy of chemotherapy using a liposome for integration of CD20 targeting, ultra-violet irradiation polymerizing, and controlled drug delivery

Cong Wu†, Huafei Li†, He Zhao†, Weiwei Zhang†, Yan Chen†, Zhanyi Yue†, Qiong Lu†, Yuxiang Wan†, Xiaoyu Tian† and Anmei Deng†

Abstract

Unlike most malignancies, chemotherapy but not surgery plays the most important role in treating non-Hodgkin lymphoma (NHL). Currently, liposomes have been widely used to encapsulate chemotherapeutic drugs in treating solid tumors. However, higher in vivo stability owns a much more important position for excellent antitumor efficacy in treating hematological malignancies. In this study, we finely fabricated a rituximab Fab fragment-decorated liposome based on 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC8,9PC), which can form intermolecular cross-linking through the diacetylenic group by ultra-violet (UV) irradiation. Our experimental results demonstrated that after the UV irradiation, the liposomes exhibit better serum stability and slower drug release with a decreased mean diameter of approximately 285 nm. The cellular uptake of adriamycin (ADR) by this Fab-navigated liposome was about four times of free drugs. Cytotoxicity assays against CD20+ lymphoma cells showed that the half maximal (50%) inhibitory concentration (IC50) of ADR-loaded immunoliposome was only one fourth of free ADR at the same condition. In vivo studies were evaluated in lymphoma-bearing SCID mice. With the high serum stability, finely regulated structure, active targeting strategy via antigen-antibody reaction and passive targeting strategy via enhanced permeability and retention (EPR) effect, our liposome exhibits durable and potent antitumor activities both in the disseminated and localized human NHL xeno-transplant models.

Keywords: Non-Hodgkin lymphoma; Rituximab; Chemotherapy; Liposomes; Serum stability; Ultra-violet irradiation polymerizing

Background

Non-Hodgkin lymphoma (NHL) is a type of blood cancer, which presents not only as a solid tumor of lymphoid cells in lymph nodes and/or extranodal lymphatic organs such as spleen and bone marrow, but also as free lymphoma cells in circulating blood [1-3]. Particularly, most patients can be cured with chemotherapy and/or radiation, which revealed the important status of chemotherapy in the treatment of NHL [4-6]. Currently, while various chemotherapeutic agents are validated to be effective in the treatment of lymphoma in preclinical studies, clinical applications are often limited for their side effects to normal tissues because of the systemic administration. As a result, finding more effective strategy to maximize the curative effect while minimizing the side effects of chemotherapy against lymphoma is of great importance and urgency [7,8].

In the past decade, nanocarriers, including liposomes, polymeric nanoparticles, micelles, nanogels etc., with an appropriate diameter of tens to hundreds of nanometers, have received widespread attention for the specific delivery of bioactive reagents in the diagnosis and treatment of cancer [7,9-12]. Encapsulation of bioactive reagents in nanocarriers can result in significant accumulation and...
retention in solid tumor tissues relative to administration of drug in conventional formulations through the enhanced permeability and retention (EPR) effect, which was firstly described by Maeda and colleagues [13-17]. What's more, the drug loading nanocarriers owns high serum stability, which can contribute to long-time circulation in the blood vessels, resulting in long-lasting antitumor activities, especially for the killing of free malignant cells in circulating blood [12,17,18]. However, more and more laboratory researches and clinical studies have demonstrated that passive targeting strategy alone is not enough for more sufficient and efficient accumulation of drug-loading nanocarriers in some tumor types [19-21].

Following the FDA approval of anti-CD20 mAb Rituximab for CD20+ NHL treatment, monoclonal antibody (mAb)-based targeting therapy has revolutionized the treatment of malignancies for the specific antitumor activity and low cytotoxicity against normal tissues [22,23]. In the last decade, more and more studies have confirmed that the combination of mAb-based active targeting and nanoparticle-based passive targeting can improve drug concentration in tumor tissues and tumor cells in a shorter time with greater accuracy [7,24,25].

In this study, we have developed an adriamycin (ADR)-loaded liposome using the diacetylenic phosphatidylcholine 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC8,9PC, hereafter referred to as PC), which can form intermolecular cross-linking through the diacetylenic group to produce a conjugated polymer within the hydrocarbon region of the bilayer by ultra-violet (UV) irradiation (Additional file 1: Figure S1) [26,27]. For the sake of active targeting, the Fab fragments of rituximab were conjugated onto the liposomal surface. Our experimental results demonstrate that this well-modified liposome, which owns good serum stability and prolonged circulation time, can accumulate in the tumor tissues and malignant cells with high specificity and sufficient amount, which can bring out exceptional excellent and durable therapeutic efficacy against CD20-positive lymphomas.

**Methods**

**Cell lines and materials**

Two human B cell lymphoma cell lines, Raji and Daudi, were obtained from the American Type Culture Collection (ATCC). Cells were propagated and maintained in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (FBS, Gibco, Invitrogen, Carlsbad, CA, USA) in a controlled atmosphere incubator at 37°C with 5% CO2. The DC8,9PC and 1,2-diesteroyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (Mal-PEG) were purchased from Avanti Polar Lipids (Williamsport, PA, USA). The anti-CD20 antibodies rituximab was purchased from Roche (Basel, Switzerland).

**Fabrication of Fab fragment-conjugated liposome**

**Formation of drug-loaded liposomes**

Total lipids mixtures of 2 mg DC8,9PC and 0.25 mg Mal-PEG were dissolved in 500 μL mixed solvent of chloroform and methyl alcohol with the volume ratio at 1:1. Then, the solvent was evaporated under vortex and flushed with nitrogen to obtain the lipid film, followed by washing-out with 2 mL of ADR (doxorubicin HCl, Melonapharma CO. LTD., Dalian, China) solution (0.5 mg/mL in PBS) to obtain ADR-loaded multilamellar vesicles [26]. The collected liposome solution was dialyzed against PBS using a membrane (molecular weight cutoff 3 kDa) at 4°C for 12 h to remove uncombined ADR resulting in the ADR-loaded liposome stock solutions.

**Thiolation of mAbs**

The Fab fragment of rituximab was prepared as reported previously [25]. Briefly, 10 mg/mL Rituximab was incubated with 0.25 mg/mL de pepsin at 37°C overnight following with a centrifugation and dialysis against TBS (145 mM NaCl and 10 mM Tris, pH 7.5) for 18 h. The Staph A-Sepharose column (Pharmacia, Kalamazoo, MI, USA) was used to remove the undigested mAbs at pH 8.0 resulting in the rituximab F(ab)_2. The obtained F(ab)_2 was further purified by the Sephadex G-150 column (Pharmacia, MI, USA) which was pre-equilibrated by the buffer 1 (0.1 M NaCl, 0.1 M borate, 0.05 M citrate and 2 mM EDTA, pH 5.5). Such F(ab)_2 solution was concentrated to 10 mg/mL and further digested by the enzyme papain. The Fab fragment solution was purified by the same procedure as mentioned above resulting in the single Fab fragment stock solution storing at 4°C.

To activate the Fab fragments of rituximab for reactivity toward the maleimide, the above stock solutions were incubated with 2-iminothiolane (2-IT, Sigma-Aldrich, St. Louis, MO, USA) with a mass ratio of 1:0.15 (Fab/2-IT) at room temperature for 2 h under a gentle shake. Unreacted 2-IT was removed by dialysis. The bovine serum albumin (BSA) ~ SH was produced in the same way. The resulting reactive Fab ~ SH and BSA ~ SH were stored at 4°C for future usage [28].

**Fabrication of rituximab Fab-conjugated liposome**

The Fab fragment-conjugated liposome was prepared by coupling the reactive Fab ~ SH onto the liposomal surface via the reaction between the ~ SH and Mal-group at 4°C and N2 environment overnight; the un-conjugated Fab were removed by dialysis. The BSA-conjugated liposome was fabricated in the same way. For UV irradiation, pure liposome solutions were exposed to 20 irradiation cycles at 4°C, with a 254-nm UV light dose of 360 mJ/cm² per cycle using a Stratalinker-UV 1800 [26]. The concentration of Fab fragments in the liposome solution was...
quantified by measuring the A260/A280 using NanoVue\textsuperscript{TM} (GE Healthcare, Wilmington, MA, USA).

**Characterization of Fab fragment-conjugated liposome**

The hydrodynamic diameter and size distribution were determined by ZetaSizer (Nano-ZS, Malvern Instruments, Worcestershire, UK) equipped with a HeNe laser (633 nm) at the scattering angle 173°. To prepare stained specimens for TEM (H-7000 Electron Microscope, Hitachi, Tokyo, Japan) experiments, about 5 μL liposome solution was dropped on 200-mesh Formvar-free carbon-coated copper grids (Ted Pella Type-A; nominal carbon thickness 2 to 3 nm). After the water evaporating by exposing to air at room temperature, the sample was inversely covered on a small drop of hydroated phosphotungstate (PTA) solution with a mass fraction of 2%. The conventional TEM images were obtained at 100 kV.

**Weight-average molecular weight analysis by SLS**

The static light scattering (SLS) measurements were carried out varying the scattering angle (θ) from 40 to 140° with a 5° stepwise increase [29]. The weight-average molecular weight ($M_w$) was estimated from the following equation [30]:

$$\frac{Kc_p}{R(q)} = \frac{1}{M_w} + 2A_2c$$

where $K = \frac{4\pi^2n^2(dn/dC_p)^2}{N_A\lambda^4}$ is optical contrast, with $n$ being the refractive index of solvent, $c_p$ the liposomal concentration, $dn/dC_p$ the refractive index increment against $C_p$, determined by a double beam differential refraction meter (DMR-1021) (Otsuka Electronics, Tokyo, Japan), $\lambda$ the incident wavelength, and $N_A$ the Avogadro’s number. $R(q)$ is the Rayleigh ratio at a specific measurement angle. By measuring $R(q)$ for a set of θ and $c_p$, values of $M_w$ and $A_2$ were estimated from typical Zimm plots.

**ADR releasing profile**

A dialysis bag (molecular weight cutoff 1 kDa) containing 3 mL PC-ADR solution before or after UV irradiation was respectively put in a beaker with 500 mL PBS. The beaker was fixed in a water bath kept at 37°C with continues siring. About 500 μL PBS solution outside the dialysis bag was sampled at different time intervals, which was measured by UV at 480 nm to determine the ADR concentration. The cumulative drug release was calculated by the following function:

$$\text{Cumulative release} = \frac{C_{\text{Outside dialysis bag}} \times 500 \text{ mL}}{C_{\text{Inside dialysis bag}} \times 3 \text{ mL}} \times 100\%$$

**Serum stability evaluation by DLS**

For evaluating the effect of UV irradiation on the liposomal stability, a bovine serum albumin (BSA) solution in RPMI 1640 with a concentration of 50% (m/v) was used as an in vitro serum model to mimic the in vivo status. Then, the irradiation (irrad) and non-irrad liposome solutions were separately mixed with the resulting serum model at 37°C for 24 h. The dynamic light scattering (DLS) was used to measure the size and size distribution profile of BSA/liposome mixture at 0 and 24 h, respectively.

**Cellular uptake and internalization assays**

Raji and Daudi cells were seeded into a 48-well microplate (1 × 10\textsuperscript{5} cells) and incubated with 1 μg/mL free ADR, ADR-loaded liposomes decorated with Fab fragments (PC-ADR-Fab), or BSA (PC-ADR-BSA) in cell culture medium containing 1% (v/v) antibiotics at 37°C for 4 h.
Cells incubated with culture medium were used as a negative control. After washing with PBS for twice, a FACScan Flow Cytometer (Becton Dickinson, San Jose, CA, USA) was used to assess the cellular uptake of ADR or ADR-loaded liposomes by detecting the mean fluorescence intensity (MFI) of FL-2 (ADR fluorescence). Additionally, each sample was also visualized using an inverse fluorescence microscopy.

**In vitro cytotoxicity assay**

Cytotoxicity assessment was carried out on Raji and Daudi cells using a Cell Counting Kit-8 (CCK-8, Beyotime Institute of Biotechnology, Shanghai, China) assay. Briefly, cells were seeded in a 96-well plate at an initial density of 3,000 cells/well in 100 μL of RPMI-1640 supplemented with 10% (v/v) heat-inactivated FBS, 1% (v/v) antibiotics, and different concentrations of free ADR, PC-ADR-BSA, or PC-ADR-Fab or the corresponding concentration of rituximab Fab. After 48 h, 10 μL CCK-8 was added to each well for another 2-h incubation protected from light. The absorbance (Ab) at 450 nm was recorded by a micro-plate reader (Thermo Multiskan MK3, Thermo Scientific, Waltham, MA, USA), and cell viability was calculated as the following function:

\[
\text{Cell viability}\% = \frac{(A_{\text{Blank}} - A_{\text{Blank}})}{(A_{\text{Control}} - A_{\text{Blank}})} \times 100\%
\]

where \(A_{\text{Blank}}\), \(A_{\text{Control}}\), and \(A_{\text{Sample}}\) are the absorbance values of each sample, the cells cultured in culture medium without any additional substances, and the culture medium without cells in wells, respectively.

**Animals**

Healthy female SCID mice aged about 4 weeks were purchased from Shanghai Experimental Animal Center of Chinese Academy of Sciences (Shanghai, China), housed in specific pathogen-free conditions, and treated in accordance with guidelines of the Committee on Animals of Shanghai Hospital affiliated to the Second Military Medical University (Shanghai China).

**Pharmacokinetics and in vivo distribution analysis**

The pharmacokinetics (PK) and in vivo distribution analysis was done following Joseph M. Tuscano’s study with minor revisions [31]. Briefly, Daudi cells (1 × 10^7) were inoculated subcutaneously into the right flank of 6-week-old SCID mice. For PK assays, when tumors reached about 50 to 60 mm^3 in volume (approximately 14 days), mice were randomly administrated tail vein injection of free ADR, non-irrad or irradi ADR-containing immunoliposomes at a dosage of 5 mg ADR/kg (n = 3 mice per treatment). Then, 10 μL of blood were collected through tail vein nicking from each mouse at 5, 15, and 30 min and 1, 2, 4, 6, 8, 12, 24, and 48 h after treatment, respectively. Samples were immediately diluted into 250 μL of 0.5 mmol/L EDTA-PBS, followed by a centrifugation (300 g × 5 min). Plasma was collected and ADR was extracted by acidified isopropanol (75 mmol/L hydrochloric acid in 90% isopropanol) at 4°C for 20 h. The ADR concentrations were measured by UV at 480 nm and expressed as micrograms per milliliter (ADR/blood plasma). The data were analyzed by the PK solver software [32]. For biodistribution assays, tumor-bearing mice were randomly administrated tail vein injection of free ADR, PC-ADR-BSA, or PC-ADR-Fab at a dosage of 5 mg ADR/kg (n = 3 mice per treatment). Mice were sacrificed 24 h after treatment; part of tumor, heart, liver, spleen, kidneys, and lungs were removed, washed, and weighed; and single-cell suspensions were made. ADR was extracted from cells by the abovementioned acidified isopropanol for 20 h at 4°C. The ADR concentrations were determined as described above and expressed as micrograms per gram (ADR/tissue). What’s more, part of the tumor tissues were collected and subjected to frozen sections, which were detected by a confocal microscope (Zeiss, Oberkochen, Germany).

**In vivo antitumor activity assessment in disseminated human NHL xeno-transplant models**

Six-week-old SCID mice were injected via the tail vein with 5 × 10^6 Daudi cells in 100 μL PBS. Then, the inoculated mice were randomly assigned to 4 groups with 10 each for the treatment of PBS, free ADR, PC-ADR-BSA, and PC-ADR-Fab (with an equivalent amount of 5 mg/kg ADR) via the tail vein weekly for 3 times after 48 h. Post-operation monitoring was exercised at least once a day until natural death in a range of 120 days. Survival curves were plotted with the Kaplan-Meier method and compared by using a log-rank test [33,34].

**In vivo antitumor activity assessment in localized human NHL xeno-transplant models**

Daudi cells (1 × 10^7) in 100 μL of PBS buffer were inoculated subcutaneously into the lateral flank of 6-week-old SCID mice. When the tumors reached about 50 to 60 mm^3 in volume, the inoculated mice were randomly assigned to four groups with four each for the treatment of PBS, free ADR, PC-ADR-BSA, and PC-ADR-Fab (with an equivalent amount of 5 mg/kg ADR) via the tail vein weekly for three times. Post-operation monitoring was exercised at least once a day, and the tumor size was measured in two perpendicular diameters with precision calipers every 3 days and calculated in a range of 60 days. Tumor volume was measured according to the following formula [25]:

\[
\text{Tumor volume} = \text{Length} \times \text{Width}^2/2
\]
where length and width refers to the longest and the shortest diameters of tumors, respectively.

**Statistical analysis**

Data were expressed as the means ± standard deviation (SD). Statistical analysis was performed by Student’s t test or one way ANOVA to identify significant differences unless otherwise indicated. Differences were considered significant at a *P* value of <0.05.

**Results**

**Characterization of the liposome**

It has been firmly established that size distribution of a liposome strongly affect its *in vitro* and *in vivo* performances [17,25]. Therefore, we firstly assessed the size distribution of our liposome after the successful fabrication. Figure 2A shows the size distribution of irrad and non-irrad liposomes. It was illustrated that an 11% decrease in mean size was occurred after UV irradiation (from approximately 321 nm before irradiation to 285 nm after irradiation). This interesting physical change was validated by morphology analysis using a TEM, of which the results suggested that both the irrad and non-irrad liposome showed a regular spherical morphology with different diameters (Figure 2B).

**Fab fragment loading**

The number of Fab fragments per liposome was estimated on the basis of Kozlowska’s ideas according to the following equation [35]:

\[
\text{Fab fragments per liposome} = \frac{\text{Fab molecules per mL}}{\text{liposomes per mL}}.
\]

Firstly, the liposomal *Mw* was estimated to be 1.22 × 10^7 g/mol by SLS analysis (Table 1), and the Fab concentration in liposome solution was quantified to be 52.2 μg/mL by determining the A260/A280 by Nano VueTM. Besides, the total mass of liposomes in the suspensions (total volume 2.85 mL) can be calculated from the original polymer amount of 2 mg PC and 0.25 mg Mal-PEG plus the detected amount of Fab (52.2 μg/mL × 2.85 mL) to be approximately 2,398.8 μg. The total mass of liposomes per milliliter can be calculated to be 841.7 μg (2,398.8 μg/2.85 mL). Accordingly, we can estimate that there are 6.9 × 10^-11 mol [841.7 μg/(1.22 × 10^7 g/mol)] or 4.15 × 10^13 liposomes per milliliter.

The number of Fab fragments (24 kDa) per milliliter calculated in the same way was 2.2 × 10^-9 mol [52.2 μg/ (2.4 × 10^4 g/mol)] or 1.3 × 10^15. Hence we can estimate that there are on average ~31.3 Fab fragments per milliliter.
Drug loading and releasing properties

It was well expected that our liposome could be an excellent drug carrier which benefits from the stable structure following by self-assembling and UV irradiation functions. For the validation of this expectation, we firstly evaluated the ADR loading content (LC) of our liposomes according to the following function:

\[
\text{Loading Content (LC)} = \frac{C_{\text{ADR}}}{C_{\text{polymer}}} \times 100\%.
\]

The results revealed a relative high LC of 16.27% with our immunoliposomes. Besides, the amount of ADR per liposome was estimated to be \(3.1 \times 10^{-9}\) ng (Table 1), which was calculated according to the following equation:

\[
\text{ADR/liposome} = \frac{\text{ADR ng}}{\text{liposome per mL}} = \frac{\text{ADR ng}}{\text{liposomes per mL}}.
\]

Also, the drug release profiles were determined in PBS buffer at a PH value of 7.4 at 37°C. As expected (Figure 2C), slower drug release from the irrad liposomes was observed comparing with non-irrad liposomes. This controlled drug release can be attributed to the polymerization of PC by UV light irradiation. Otherwise, approximately 62%, 73%, 84%, 88%, and 91% of ADR was respectively released from the irrad liposomes after 24, 48, 72, 96, and 120 h, the fact of which ensures sufficient drug release at the tumor site, especially in tumor cells.

Low cytotoxicity of liposomes

For the determination of the cytotoxicity, different concentrations of empty liposomes decorated by BSA (PC-BSA) and rituximab Fab fragments (PC-Fab) were incubating with Raji cells at 37°C for 48 h following by a CCK-8 detection. As illustrated in Figure 2D, both the PC-BSA and PC-Fab showed low cytotoxicity to Raji cells in concentrations of up to 32 μg/mL. It is worth mentioning that the cell viability of PC-Fab-incubated cells had a little decrease compared with PC-BSA-incubated cells, which may be related with the weak tumor suppression effect of rituximab Fab fragments.

Serum stability evaluation

For future clinical applications, the in vivo stability of liposome is another important factor which should be considered. Therefore, we used the RPMI 1640 containing 50% BSA as an in vitro model of serum to check the serum stability profile of our liposomes, in which the existence of BSA was employed to mimic a variety of serum proteins in the complicated environment within the blood vessels. Figure 3 shows the size distribution of liposome solutions before (red) and after (black) UV irradiation. The first individual peak in each histogram represents the size distribution of BSA, and the second represents that of liposomes. The results indicated that after the dilution of liposomes in serum model, the size distribution of each sample was similar as separately measured (Figure 3A), while after a 24-h incubation, the well-separated peaks for BSA and liposomes still appeared in the mixture, which is an indication of good serological stability. However, the non-irrad liposomes in the mixture showed a much broader size distribution (Figure 3B). The results revealed that after the UV irradiation, our liposomes showed better stability in the serum model than non-irrad ones.

Intracellular uptake of liposomes

For the evaluation of intracellular uptake of our CD20-targeting liposomes, the ADR-loaded liposomes, PC-ADR-BSA and PC-ADR-Fab, were incubated with CD20+ Raji and Daudi cells for 4 h. After washing, the flow

| Table 1 Physicochemical parameters of ADR-loaded immunoliposomes |
|------------------------|-----------------|------------------|-----------------|------------------|
| \(R_h\) (nm) | PDI | \(M_w\) (g/mol) | \(N_{\text{agg}}\) | Fab/liposome | ADR (ng)/liposome |
| 141.3 | 0.055 | \(1.22 \times 10^7\) | 1,151 | 31.3 | \(3.1 \times 10^{-9}\) |

\(R_h\), averaged radius; PDI, particle dispersion index; \(M_w\), weight-average molecular weight; \(N_{\text{agg}}\), the liposomal aggregation number; Fab/liposome, Fab fragments per liposome; ADR/liposome, ADR mass per liposome.
cytometer (FCM) and inverse fluorescent microscopy were used to evaluate the ADR fluorescence (red) in lymphoma cells. As indicated by the mean fluorescence intensity (MFI) of FL-2 (Figure 4A), the PC-BSA (green histograms) and PC-Fab (blue histograms) significantly enhanced the intracellular uptake of ADR compared with free drugs (red histograms) (**p = 0.000), while the increasing extent of PC-Fab is much higher than that of PC-BSA (**p = 0.000). This result was confirmed by the inverse fluorescent microscopy as displayed in Figure 4B.

In vitro cytotoxicity assays

The in vitro antitumor activities of our liposomes were subsequently evaluated. After the incubation of Raji and Daudi cells with different concentrations of free ADR, rituximab Fab fragments, PC-ADR-BSA, and PC-ADR-Fab for 48 h, a CCK-8 assay was employed to determine the cell viability. As illustrated in Figure 5A,B, both Raji and Daudi cells showed a significantly lower cell viability after the treatment of drug-loaded liposomes compared with free ADR, while PC-ADR-Fab exhibited more potent antitumor activity compared with PC-ADR-BSA in all the tested ADR concentrations. Because the therapeutic effects of rituximab is largely dependent on the Fc-related antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC) [36], the Fab fragments demonstrated low cytotoxicity in both Raji and Daudi cells in all the tested concentrations (0.005 to 1.3 μg/mL), which corresponded to the ADR concentrations in the liposomal system. Furthermore, the half maximal (50%) inhibitory concentration (IC50) of ADR was calculated to evaluate the cytotoxicity of the liposomal drug delivery systems according to the ADR concentration dependence of the cell viability profile. It was shown in Figure 5C that PC-ADR-Fab demonstrated the lowest IC50 to Raji (0.103 μg/mL) and Daudi (0.094 μg/mL) cells compared with PC-ADR-BSA (IC50Raji 0.208 μg/mL, IC50Daudi 0.229 μg/mL) and free ADR agents (IC50Raji 0.436 μg/mL, IC50Daudi 0.441 μg/mL).

Pharmacokinetics of ADR-containing liposomes in tumor bearing SCID mice

After a short injection of free ADR and ADR-containing liposomes at 5 mg/kg into lymphoma-bearing SCID mice, the plasma ADR concentrations were measured at different time intervals. The data were analyzed using the PK solver software [32] and the results are all fitted to a trilocular pattern [37]. The time-concentration curve is shown in Additional file 2: Figure S2 and the PK parameters in Table 2. As we can see, a remarkable difference in plasma PK was observed after the tail vein administration of free and liposomal ADR. The t½γ (the elimination half time in the elimination phase) was relatively longer for irrig liposomes (34.53 ± 2.63 h) than that for non-irrig liposomes (21.13 ± 1.50 h) and free ADRs (9.56 ± 4.06 h). In contrast, the clearance (CL) was significantly reduced for irrig liposomes (6.63 ± 3.74 ml/h versus CLnon-irrig liposomes 8.82 ± 4.54 ml/h, CLfree drugs 30.96 ± 5.86 ml/h).

Figure 4 Cellular uptake and intracellular accumulation of ADR-loaded liposomes. (A) Detection of ADR fluorescence intensity by FCM. Up panel: the histogram represents the fluorescence intensity distribution of Raji and Daudi cells. Black histogram, no-treat; red histogram, free ADR treatment; green, PC-ADR-BSA treatment; blue, PC-ADR-Fab treatment. Down panel: Numerical data representing the mean fluorescence intensity (MFI) of ADR fluorescence in Raji and Daudi cells. Data are mean ± SD of at least three experiments. (B) The effects of liposomes on the intracellular uptake indicated by the inverse fluorescent microscopy. Red fluorescence represents the intracellular ADR. Scale bar 50 μm.
In vivo distribution and tumor accumulation assays

In order for *in vivo* distribution and tumor accumulation assays, lymphoma-bearing SCID mice were injected with free ADR and ADR-loaded liposomes (PC-ADR-BSA and PC-ADR-Fab) via tail vein. Twenty-four hours after treatment, tissues were harvested and the sum total ADR was extracted and measured. Figure 6A shows that there was a significant increase in tumor ADR accumulation in PC-ADR-Fab compared with PC-ADR-BSA (*p = 0.048) and free ADR-treated mice (**p = 0.000). The heart, liver, spleen, and lungs all showed less ADR accumulation with liposomal ADR treatment than with free ADR treatment. There was no difference in ADR accumulation among treatments for the kidneys. The displayed fluorescent image of different frozen sections (Figure 6B) also demonstrated distinct enhancement of red fluorescence in tumor tissues of mice treated with ADR-loaded liposomes compared with that treated with free ADR, and the administration of PC-ADR-Fab can induce more retention of ADR in tumor tissues than the administration of PC-ADR-BSA for the active targeting of Fab fragments.

In vivo antitumor activity assessment

For the evaluation of *in vivo* antitumor activities, both the disseminated and localized human NHL xeno-transplant models were set up. In the localized model, Daudi cells were inoculated subcutaneously in the right flank of SCID mice. When the tumors reached about 50-60 mm³ in volume, mice were randomly treated with free ADR, PC-ADR-BSA and PC-ADR-Fab with an equivalent ADR amount of 5 mg/kg [25,38]. The mice were treated once a week for SCID mice based on previous study and our preliminary experimental results [39]. The tumor volume was recorded and illustrated in Figure 6C. Our results indicated that mice treated with PC-ADR-Fab and PC-ADR-BSA demonstrated a remarkable decrease in tumor burden compared with free ADR and control treatment as measured by tumor volume. Otherwise, PC-ADR-Fab exhibit a more excellent antitumor ability comparing with PC-ADR-BSA, with 2/4 mice of complete remission (CR) indicated by no measurable mass.

The excellent antitumor activity of our liposome is validated using a disseminated model, in which Daudi cells were transplanted intravenously into SCID mice via tail

---

Table 2 Tumor bearing nude mice serum pharmacokinetic parameters comparing free and liposomal ADRs (*n = 3*)

| Parameter | Unit | Free ADR | Non-irrad | Irrad |
|-----------|------|----------|-----------|-------|
| $t_{1/2\alpha}$ | h | 0.20 ± 0.02 | 0.19 ± 0.04 | 0.21 ± 0.05 |
| $t_{1/2\beta}$ | h | 0.98 ± 0.19 | 3.89 ± 0.79 | 1.57 ± 1.31 |
| $t_{1/2\gamma}$ | h | 9.56 ± 4.06 | 21.13 ± 1.50 | 34.53 ± 2.63 |
| CL | mL/h | 30.96 ± 5.86 | 8.82 ± 4.54 | 6.63 ± 3.74 |
| $C_{\text{max}}$ | μg/mL | 50.45 ± 5.54 | 54.13 ± 4.34 | 53.04 ± 5.68 |
| AUC₀⁻­t | (μg/mL)·h | 79.97 ± 11.36 | 447.19 ± 54.19 | 713.49 ± 120.51 |
| MRT | h | 6.37 ± 2.15 | 27.54 ± 1.53 | 48.58 ± 4.67 |

$t_{1/2}$, the elimination half time; CL, clearance; $C_{\text{max}}$, the maximum observed concentration in the plasma; AUC, area under the concentration-time curve; MRT, mean residence time.
After 48 h, these mice were randomly administered injections of PBS, free ADR, PC-ADR-BSA, and PC-ADR-Fab for three times once a week. Survival curves were plotted with the Kaplan-Meier method and were compared by using a log-rank test [33,34]. As illustrated in Figure 6D, ADR-loaded liposome (PC-ADR-BSA and PC-ADR-Fab) treatment significantly prolonged the survival of tumor-bearing mice compared to free ADR and PBS control treatment (*p < 0.05). As our expectation, comparing with PC-ADR-BSA treatment, the administration of PC-ADR-Fab led to significant prolongation of graft survival days (*p < 0.05), with a CR percentage of 4/10 indicated by long-term survival (>120 days post-treatment).

**Discussion**

NHL presents not only as a solid tumor of lymphoid cells in lymph nodes and/or extranodal lymphatic organs, but also as free lymphoma cells in circulating blood [1-3]. Unlike most other malignancies, chemotherapy but not surgery plays the most important role in curing NHL [4-6]. Currently, more and more studies are focusing on finding out novel drug delivery system for treating solid tumors [7,11,17,25]. However, for the elimination of free malignant cells in circulating blood, high serum stability and specificity to tumor cells are of great importance.

In this study, we have successfully fabricated a rituximab Fab-conjugated liposome based on PC, of which the well-defined spherical morphology was observed under TEM. Because PC is a kind of diacetylenic lipids, which can form intermolecular cross-linking through the diacetylenic group by UV irradiation to form chains of covalently linked lipids in the liposomal bilayers (Additional file 1: Figure S1) [26], this covalently union between lipid chains leads to a relatively more compact structure; thus, an important impact on the stability of the polymerized drug delivery system can be obtained. This enhanced serum stability can result in longer-time circulation and slower clearance of encapsulated drugs in vivo. Further experimental results
revealed a favorable biological compatibility of the liposome. All the abovementioned properties are of vital importance for an ideal drug delivery system in eliminating malignant lymphoma cells, especially those in the peripheral blood.

In order to determine the antitumor activities, we took two lymphoma cell lines, Raji and Daudi, as study targets. The experimental results demonstrated that the in vitro cytotoxicity of ADR-loaded targeting liposome (PC-ADR-Fab) was significantly promoted due to the enhancement of drug uptaking compared with free drugs and ADR-loaded non-targeting liposome. The result may be ascribed to the following two reasons. Firstly, previous studies have proven that nanoparticles are taken up by cells via clathrin and/or caveoli-mediated endocytosis unlike small molecule drugs, which were taken up by passive diffusion [40,41]. Thus, most nanoparticles can obviously enhance the intracellular uptake of chemotherapeutic agents, which was confirmed by previous studies and recognized as an important advantage of nanosized drug delivery system [25,42,43]. Secondly, the intracellular uptake could be further improved by the Fab fragments of rituximab based on the active targeting strategy by antigen-antibody identification and combination.

In vivo experimental results indicated that the immunoliposomes are selectively accumulated in tumor tissues, while the administration of free drugs resulted in high concentration of ADR in either normal or malignant tissues with no specificity. This remarkable discrepancy can significantly improve the bioavailability and reduce the detrimental cytotoxicity of chemotherapeutic agents. The in vivo antitumor experiments carried out both in the localized and disseminated human NHL xenotransplant models suggest that our immunoliposome was significantly more effective than either free ADR or non-targeting liposomal ADR in inhibiting primary tumor growth and prolonging the graft survival. What’s more, our immunoliposome still showed great advantage in tumor suppressing efficacy when compared with other drug delivery systems. For example, comparing with the anti-CD30 antibody-conjugated liposomal doxorubicin constructed by Ommoleila Molavi et al., the treatment of which can respectively decrease the tumor burden to approximately 1/7 and approximately 1/2 in comparison with PBS and free ADR treatment [44]; our immunoliposome can remarkably decrease the tumor burden to approximately 1/14 and approximately 1/4, respectively. In our opinion, this exceptional excellent in vivo antilymphoma activity of the ADR-loaded Fab fragment-decorated liposome is the cooperative action of the following effects: (1) enhanced intracellular uptake due to effective endocytosis based on well-defined liposomal structure and size distribution; (2) enhanced serum stability and controlled drug release (as a result of UV irradiation polymerizing) can contribute to long circulation time and durable antilymphoma activity; (3) enhanced tumor accumulation and retention in vivo through dual targeting function, passive targeting through EPR effects and active targeting through antigen-antibody reaction.

Conclusions
In this study, we have identified a novel liposomal drug delivery system, PC-Fab, for improved chemotherapy of CD20-positive NHL. The in vitro and in vivo experimental results clearly suggested that this Fab fragment-decorated liposome can be a promising weapon in combating NHL, which deserves further investigation for clinical application.

Additional files

Additional file 1: Figure S1. Formulation and schematic diagram. Formulation and schematic diagram of irrad and non-irrad liposomes.

Additional file 2: Figure S2. Time-concentration curve. Time-concentration curve of free and liposomal ADR by PK software.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
CW, HL, and AD designed the experimental scheme; HL and H2 performed the preparation and characterization of the liposomes. HL, HZ, WY, YC, ZY, QL, YW, and XT participated in the in vitro and in vivo cytotoxicity assay; HL drafted the manuscript; and CW and AD modified the manuscript. All authors read and approved the final manuscript.

Acknowledgement
This research was supported by grants from 973 Foundation (2013CB531606), National Science Foundation of China (81371786), Shanghai Municipal Commission for Science and Technology (11JC1410902), Youth Fund of the Second Military Medical University (2013QN14), and Wujieping Grant (320.6750.13147).

Author details
1Department of Laboratory Diagnosis, Changhai Hospital affiliated to the Second Military Medical University, 168 Changhao Road, Shanghai 200433, China. 2International Joint Cancer Institute, the Second Military Medical University, 800 Xiangyin Road, Shanghai 200433, China. 3Institute of Pediatric Research, Children’s Hospital affiliated to Soochow University, 303 Jingde Road, Suzhou 215000, China.

Received: 9 June 2014 Accepted: 23 August 2014
Published: 28 August 2014

References
1. Shankland KR, Armitage JO, Hancock BW: Non-Hodgkin lymphoma. Lancet 2012, 380:848–857.
2. Neri A, Chang CC, Lombard L, Salina M, Coradini P, Maialo AT, Chaganti RS, Dalla-Favera R: B cell lymphoma-associated chromosomal translocation involves candidate oncogene lyn-10, homologous to NF-kappa B p50. Cell 1991, 67:1075–1087.
3. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Vanghese B, Gill S, Jan M, Cha AC, Chen CK, Tan BT, Park CY, Zhao F, Kohrt HE, Makumbere R, Briones J, Giacuzyn RD, Loscos IS, Levy B, Weissman IL, Majeti R: Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 2010, 142:699–713.
4. Moncada B, Sobrevilla-Onzandar S, Md JD: Radiotherapy supports a better outcome than chemotherapy in cutaneous natural killer (NK)/T cell lymphoma nasal type. Int J Dermatol 2013, 52:1276–1277.
5. Reimer P, Chawla S. Long-term complete remission with belinostat in a patient with chemotherapy refractory peripheral T-cell lymphoma. *J Hematol Oncol* 2013, 6:69.

6. Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, Won JH, Kim MK, Kwon JH, Mun YC, Kwak JY, Kwon JM, Hwang GG, Kim HJ, Park J, Oh S, Huh J, Ko YH, Suh C, Kim WS. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphomas: surgical resection followed by chemotherapy versus chemotherapy alone. *Blood* 2011, 117:1958–1965.

7. Ganta S, Devalapally H, Shahiwala A, Arunj M. A review of stimuli-responsive nanocarriers for drug and gene delivery. *J Control Release* 2008, 126:187–204.

8. Dickerson EB, Blackburn WH, Smith MH, Kapa LB, Lyon LA, McDonald JD. *J Control Release*: Chemoselection of cancer cells by sILNA using targeted nanogel delivery. *BMC Cancer* 2010, 10:180.

9. Kang CM, Koo HJ, Lee S, Lee KC, Oh YK, Choe YS. 64Cu-Labeled tetraiodothyroacetic acid-conjugated liposomes for PET imaging of tumor angiogenesis. *Nuc Med Biol* 2013, 40:1018–1024.

10. Zhang R, Luo K, Yang J, Sima M, Sun Y, Janat-Amsbury M, Kopecek J. Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel. *Crit Rev Ther Drug Carrier Syst* 2013, 33:191–200.

11. Schlegel MC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. *Pharmacol Rev* 1999, 51:691–743.

12. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. *Crit Rev Ther Drug Carrier Syst* 1992, 9:135–187.

13. Maeda H, Matsumura Y. Tumorotropic and lymphotropic principles of macromolecular drugs. *Crit Rev Ther Drug Carrier Syst* 1989, 6:193–210.

14. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor drug targeting. *Drug Discov Today* 2005, 11:812–818.

15. Li W, Li H, Li J, Wang H, Zhao H, Zhang L, Xia Y, Ye Z, Gao J, Dai J, Wang H, Guo Y. Self-assembled supramolecular nano vesicles for safe and highly efficient gene delivery to solid tumors. *Int J Nanomedicine* 2012, 7:561–567.

16. Wang P, Zhao XH, Wang ZY, Meng M, Li X, Qin N. Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment. *Cancer Lett* 2010, 298:34–49.

17. Gabizon AA. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. *Cancer Res* 1992, 52:891–896.

18. Zheng J, Jaffrey D, Allen C. Quantitative CT imaging of the spatial and temporal distribution of liposomes in a rabbit tumor model. *Mol Pharm* 2009, 6:571–580.

19. Stapleton S, Allen C, Pintille M, Jaffrey DA. Tumor perfusion imaging predicts the intra-tumoral accumulation of liposomes. *J Control Release* 2013, 172:351–357.

20. Bhat SA, Czaucman MS. Novel antibodies in the treatment of non-Hodgkin's lymphoma. *Neth J Med* 2009, 67:311–321.

21. Maruyama D. Novel monoclonal antibodies for the treatment of malignant lymphomas. *Rinsho Ketsueki* 2011, 52:618–626.

22. Kanjo MB, Mager KA, Mirishita C, Yashiro M, Oka M, Fuji T, Komura A, Kyono K, Kamitaki M, Hiraoka K, Ochii Y, Nishiyama N, Naito A, Miyazono K. Improvement of cancer-targeting therapy using nanocarriers for intracellular solid tumors by inhibition of TGF-beta signaling. *Proc Natl Acad Sci U S A* 2007, 104:3460–3465.

23. Li W, Zhao H, Qian W, Li H, Zhang L, Ye Z, Zhang G, Xie M, Li J, Gao J, Li B, Kou G, Dai J, Wang H, Guo Y. Chemotherapy for gastric cancer by finely tailoring anti-HER2 anchored dual targeting immunomicelles. *Biomaterials* 2012, 33:5349–5362.

24. Temprana CF, Duarte EL, Taia MC, Lamy MT, Del Vas: Structural characterization of photopolymerizable binary liposomes containing diacetylenic and saturated phospholipids. *Langmuir* 2010, 26:10084–10092.

25. Wagner N, Dose K, Koch H, Ringsdorf H. Incorporation of ATP synthetase into long-term stable liposomes of a polymerizable synthetic sulfolipid. *Fets Leb* 1981, 132:313–318.